~~We Claim:~~

~~1. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use in combination therapy with gemcitabine and a platinum agent selected from cisplatin and carboplatin in the treatment of ovarian cancer.~~

~~2. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 wherein administration of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, precedes that of gemcitabine and the platinum agent.~~

3. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 or 2 wherein gemcitabine and the platinum agent are administered up to 2 days after administration of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, and gemcitabine is to be administered again up to 7 days later.

4. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 wherein administration of gemcitabine and the platinum agent precedes that of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof.

5. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to claims 1-2 wherein gemcitabine and the platinum agent are to be administered simultaneously.

6. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1-5 wherein the platinum agent is cisplatin.

7. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt

thereof, for use according to any one of claims 1-5 wherein the platinum agent is carboplatin.

8. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1-7 during a 21-day treatment cycle.

9. 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1-8 wherein the pharmaceutically acceptable salt is the dimethanesulfonate salt.

We claim:

1. Use of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-lH-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of ovarian cancer, wherein said medicament is part of a combination therapy with gemcitabine and a platinum agent selected from cisplatin and carboplatin.

2. The use of claim 1, wherein said 5-[2-tert-butyl-5-(4-fluoro-phenyl)-lH-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, is to be administered before the administration of gemcitabine and the platinum agent.

3. The use of claims 1 or 2, wherein gemcitabine and the platinum agent are to be administered up to 2 days after the administration of said 5-[2-tert-butyl-5-(4-fluoro-phenyl)-lH-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof, and the administration of gemcitabine is again up to 7 days later.

4. The use of claim 1, wherein gemcitabine and the platinum agent is to be administered before administration of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-lH-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine, or a pharmaceutically acceptable salt thereof.

5. The use of claims 1 or 2, wherein gemcitabine and the platinum agent are to be administered simultaneously.

6. The use of any of the claims 1 to 5, wherein the platinum agent is cisplatin.

7. The use of claims 1 to 5, wherein the platinum agent is carboplatin.

8. The use of claims 1 to 7, wherein said combination therapy is a 21-day treatment cycle.

9. The use of claims 1 to 8, wherein the pharmaceutically acceptable salt is the dimethanesulfonate salt.